OncoMatch/Clinical Trials/NCT05398302
Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy
Is NCT05398302 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies non-drug interventions for castration-resistant prostate carcinoma.
This clinical trial studies mechanisms of resistance to 177-lutetium prostate specific membrane antigen (177Lu-PSMA) radioligand therapy using image-guided biopsies in patients with castrate-resistant prostate cancer that had spread to other places in the body (metastatic). Diagnostic procedures, such as image guided biopsies, may help in learning how well 177Lu-PSMA works to kill tumor cells and allow doctors to plan better treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Required: Stage IV, IVA, IVB
Metastatic disease required
Demographics
Prior therapy
Must have received: radioiodine (177Lu-PSMA-617) — expanded access protocol or approved trial
Eligible for 177Lu-PSMA-617 under expanded access protocol (IRB# 21-5010) or as part of an approved trial
Lab requirements
Blood counts
Platelets > 75,000/ul within 14 days prior to biopsy; PT or INR and PTT < 1.5x ULN within 14 days prior to biopsy
Platelets > 75,000/ul within 14 days prior to biopsy; PT or INR and PTT < 1.5 times the institutional upper limit normal (ULN) within 14 days prior to biopsy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCLA / Jonsson Comprehensive Cancer Center · Los Angeles, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05398302 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received radioiodine.
What disease stage is eligible?
Stage IV or IVA or IVB is required (metastatic disease required).
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages